Synaptic Resilience Enhancement Protocol

Migration, Crosslink

📖

Synaptic Resilience Enhancement Protocol

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-synaptic-resilience-enhanceme

📖 Wiki Page

idea594 wordssynced 2026-04-02

Synaptic Resilience Enhancement for Pre-Symptomatic Neurodegeneration Prevention

Overview

This therapeutic concept proposes synaptic resilience enhancement for individuals identified as pre-symptomatic for neurodegenerative diseases. By targeting synaptic proteins (neurogranin), receptors, and downstream signaling pathways before significant synapse loss occurs, this approach aims to preserve cognitive function and prevent progression to clinical disease.[@masliah2001]

Rationale

Synapse loss correlates with cognitive decline: Post-mortem studies show synapse loss is the strongest correlate of cognitive impairment in both AD and PD[@spiresjones2014]
Neurogranin is an early biomarker: Elevated CSF neurogranin predicts future cognitive decline in pre-symptomatic individuals[@kvartsberg2015]
Synaptic plasticity is modifiable: NMDA receptor modulation, BDNF signaling, and synaptic protein synthesis can be enhanced pharmacologically[@malenka2004]
Early intervention critical: Synapse loss becomes irreversible once advanced; pre-symptomatic intervention offers the best chance of preservation[@selkoe2002]

Mechanistic Logic

```mermaid
flowchart TD
subgraph Risk_Identification
A["Cognitive Testing<br/>RAVLT, ECAS"] --> B["CSF Neurogranin<br/>Elevated = synaptic vulnerability"]
B --> C["High Synaptic Risk"]
end

...

Synaptic Resilience Enhancement for Pre-Symptomatic Neurodegeneration Prevention

Overview

This therapeutic concept proposes synaptic resilience enhancement for individuals identified as pre-symptomatic for neurodegenerative diseases. By targeting synaptic proteins (neurogranin), receptors, and downstream signaling pathways before significant synapse loss occurs, this approach aims to preserve cognitive function and prevent progression to clinical disease.[@masliah2001]

Rationale

Synapse loss correlates with cognitive decline: Post-mortem studies show synapse loss is the strongest correlate of cognitive impairment in both AD and PD[@spiresjones2014]
Neurogranin is an early biomarker: Elevated CSF neurogranin predicts future cognitive decline in pre-symptomatic individuals[@kvartsberg2015]
Synaptic plasticity is modifiable: NMDA receptor modulation, BDNF signaling, and synaptic protein synthesis can be enhanced pharmacologically[@malenka2004]
Early intervention critical: Synapse loss becomes irreversible once advanced; pre-symptomatic intervention offers the best chance of preservation[@selkoe2002]

Mechanistic Logic

Mermaid diagram (expand to render)

Target Population

| Risk Category | Profile | Age Range | Biomarker Criteria |
|---------------|---------|-----------|-------------------|
| High Risk | Family history + elevated neurogranin | 50-70 | CSF neurogranin > elevated |
| Moderate Risk | Genetic risk (APOE4/LRRK2) | 45-65 | Normal cognition, subtle deficits |
| Prodromal | MCI with biomarker evidence | 55-75 | MCI, positive AD/PD biomarkers |

Key Components

Pharmacologic Interventions

Low-dose memantine: Sub-antagonistic NMDA doses that enhance synaptic plasticity without causing adverse effects[@lipton2007]

Lobeline: Amphetamine derivative that enhances dopamine release and protects synapses[@teng2010]

NSI-189: Novel compound that promotes hippocampal neurogenesis and synaptic protein expression[@fischer2017]

Sage-217 (SAGE-217): GABA-A modulator in development for cognitive enhancement[@gunther2018]

Amplification Approaches

CK2 inhibition: Enhance synaptic protein synthesis and stability[@giese2012]
mGluR5 positive allosteric modulators: Enhance glutamate-dependent plasticity[@conn2009]
PDE5 inhibitors: Enhance cGMP signaling to support synaptic plasticity[@prickaerts2017]

Non-Pharmacologic Adjuncts

Cognitive training: Structured cognitive exercises to maintain synaptic networks
Aerobic exercise: Increases BDNF and promotes synaptic plasticity[@cotman2002]
Sleep optimization: Sleep-dependent synaptic downscaling and memory consolidation

Monitoring Biomarkers

CSF: Neurogranin, synaptic vesicle proteins (SV2C, synaptotagmin)
Blood: BDNF, NFL for general neurodegeneration
Imaging: Synaptic PET (SV2A ligands), FDG-PET for hypometabolism
Cognitive: RAVLT, ECAS, MDS-UPDRS cognitive subscale

Clinical Trial Design

| Phase | Design | Population | Primary Endpoint |
|-------|--------|------------|-----------------|
| II | Randomized, placebo-controlled | Elevated neurogranin, age 50-75 | Change in synaptic PET at 12 months |
| III | Factorial design | Pre-symptomatic at-risk | Time to cognitive impairment |

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Masliah et al., Synaptic pathology in AD (2001) (2001)](https://doi.org/10.1001/archneur.58.12.1865)

[Unknown, Spires-Jones & Hyman, Synapse loss in AD (2014) (2014)](https://doi.org/10.1016/j.tins.2014.04.002)

[Kvartsberg et al., Neurogranin in preclinical AD (2015) (2015)](https://doi.org/10.1093/brain/awv278)

[Unknown, Malenka & Bear, LTP and LTD (2004) (2004)](https://doi.org/10.1016/j.neuron.2004.09.012)

[Unknown, Selkoe, Synaptic plasticity in AD (2002) (2002)](https://doi.org/10.1101/sqb.2002.67.333)

[Unknown, Lipton, NMDA memantine (2007) (2007)](https://doi.org/10.1038/nrd.2017.119)

[Teng et al., Lobeline for PD (2010) (2010)](https://doi.org/10.1016/j.neuropharm.2009.09.004)

[Fischer et al., NSI-189 cognitive effects (2017) (2017)](https://doi.org/10.1038/npjschz.2017.130)

[Gunther et al., SAGE-217 Phase II (2018) (2018)](https://doi.org/10.1016/j.jalz.2018.07.207)

[Unknown, Giese, CK2 and synaptic plasticity (2012) (2012)](https://doi.org/10.1007/s12017-012-8180-3)

[Conn et al., mGluR PAMs (2009) (2009)](https://doi.org/10.1016/j.tips.2009.06.006)

[Prickaerts et al., PDE5 and cognition (2017) (2017)](https://doi.org/10.1016/j.neuropharm.2016.03.041)

[Unknown, Cotman & Berchtold, Exercise and BDNF (2002) (2002)](https://doi.org/10.1016/S0301-0082(02)

📖 View canonical wiki page →

Related Entities

ideas-synaptic-resilience-enhancement

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-synaptic-resilience-enhancement
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f0049df2dfa1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-synaptic-resilience-enhancement'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

48

Outgoing

61

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Synaptic Resilience Enhancement Protocol

Synaptic Resilience Enhancement for Pre-Symptomatic Neurodegeneration Prevention

Overview

Rationale

Mechanistic Logic

Synaptic Resilience Enhancement for Pre-Symptomatic Neurodegeneration Prevention

Overview

Rationale

Mechanistic Logic

Target Population

Key Components

Pharmacologic Interventions

Amplification Approaches

Non-Pharmacologic Adjuncts

Monitoring Biomarkers

Clinical Trial Design

See Also

External Links

References

💬 Discussion